Biofrontera soars after FDA approves Germany lab for testing skin treatment

Biofrontera

13/04/2022 18:08

** Shares of drug developer  BFRI.O  rise 29.8% to $4.8
    ** U.S. FDA approves Biofrontera Pharma's laboratory in
Germany as a contract laboratory for batch control and stability
testing of skin disorder treatment, Ameluz
    ** Amulez is indicated for treatment of actinic keratosis -
rough, scaly patches on skin caused by years of sun exposure
    ** BFRI says clearance reduces dependence on third-party
suppliers and risk of production downtime and product delays
    ** Stock down ~36% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))